A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.

This success suggests that the complex interactions between therapeutic cells and their targets could lead to innovative treatments for both autoimmune diseases and cancer. Initial trials using CAR T ...

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T cells -; which have lost their cancer-fighting oomph -; consume this lactic ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant ...

People living with the disease have been given hope of lifelong relief by a new cell therapy which has had successful results ...

As the new year is here, take a look at some of the most common New Year's resolutions, with tips on how to follow through ...

Shopping for a teenage auto enthusiast or a first-time driver? Don't worry—here are some unique gift ideas they'll love to ...

UC San Francisco treated its first brain cancer patient with an experimental new CAR-T therapy discovered and manufactured at ...